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identified as an independent predictor of death in AAS both in univariate
and in stepwise logistic regression analyses (odds ratio 2.28, 95% CI
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Abstract: In acute aortic syndromes (AAS), organ malperfusion
represents a key event impacting both on diagnosis and outcome.
Increased levels of plasma lactate dehydrogenase (LDH), a biomarker
of malperfusion, have been reported in AAS, but the performance of
LDH for the diagnosis of AAS and the relation of LDH with outcome in
AAS have not been evaluated so far.
This was a bi-centric prospective diagnostic accuracy study and a
cohort outcome study. From 2008 to 2014, patients from 2 Emergency
Departments suspected of having AAS underwent LDH assay at pres-
entation. A final diagnosis was obtained by aortic imaging. Patients
diagnosed with AAS were followed-up for in-hospital mortality.
One thousand five hundred seventy-eight consecutive patients were
clinically eligible, and 999 patients were included in the study. The final
diagnosis was AAS in 201 (20.1%) patients. Median LDH was 424 U/L
(interquartile range [IQR] 367–557) in patients with AAS and 383 U/L
(IQR 331–460) in patients with alternative diagnoses (P< 0.001).
Using a cutoff of 450U/L, the sensitivity of LDH for AAS was 44%
(95% confidence interval [CI] 37–51) and the specificity was 73% (95%
CI 69–76). Overall in-hospital mortality for AAS was 23.8%. Mortality
was 32.6% in patients with LDH  450U/L and 16.8% in patients with
LDH< 450U/L (P¼ 0.006). Following stratification according to LDH
quartiles, in-hospital mortality was 12% in the first (lowest) quartile,
18.4% in the second quartile, 23.5% in the third quartile, and 38% in the, Mauro Rinaldi, M oiraghi, MD,
ia, MD, PhD
1.11–4.66; P¼ 0.025), in addition to well-established risk markers such
as advanced age and hypotension. Subgroup analysis showed excess
mortality in association with LDH  450U/L in elderly, hemodyna-
mically stable and in nonsurgically treated patients.
Plasma LDH constitutes a biomarker of poor outcome in patients
with AAS. LDH is a rapid and universally available assay that could be
used to improve risk stratification and to individualize treatment in
patient groups where options are controversial.
(Medicine 95(6):e2776)
Abbreviations: AAS = acute aortic syndrome, AD = aortic
dissection, AltD = alternative diagnosis, AUC = area under the
curve, CI = confidence interval, CRP = C-reactive protein, CTA =
computed tomography angiography, ED = Emergency Department,
IFCC = International Federation of Clinical Chemistry and
Laboratory Medicine, IMH = intramural aortic hematoma, IQR =
interquartile range, LDH = lactate dehydrogenase, LR = negative
likelihood ratio, LRþ = positive likelihood ratio, NPV = negative
predictive value, OR = odds ratio, PAU = penetrating aortic ulcer,
PPV = positive predictive value, ROC = receiver operated
characteristic, TEE = transesophageal echocardiography.
INTRODUCTION
A cute aortic syndromes (AAS), which include acute aorticdissection (AD), intramural aortic hematoma (IMH), and
penetrating aortic ulcer (PAU), are cardiovascular emergencies
affecting5/100,000 individuals/y. Tominimize the heavymor-
bidity and mortality associated with AAS, key factors are
represented by rapid diagnosis and individualization of thera-
peutic interventions.1,2 The diagnosis ofAAS is challenging,with
a misdiagnosis rate as high as 39%, as the clinical manifestations
of AAS are unspecific andmost diseases in differential diagnosis
are by far more frequent than AAS.3 Therapeutic individualiza-
tion also constitutes a challenge, with increasing proportions of
patients with AAS presenting with advanced age, comorbidities,
andAAS typesnot requiring immediate surgical treatment.Organ
malperfusion has emerged as a key risk factor for adverse out-
come, but standardized definition and assessment of organ per-
fusion in AAS is presently lacking.4,5 In this scenario, circulating
biomarkers are advocated to improve diagnosis, risk stratifica-
tion, and mortality prediction in AAS, as in other acute cardio-
vascular emergencies such as acute coronary syndromes and
pulmonary embolism.6–9
Lactate dehydrogenase (LDH) is a widely expressed intra-
h reduces pyruvate to lactate during
t of plasma LDH levels is rapidly and
lable to Emergency Departments (EDs),
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with increased LDH typically found in hemolysis and in
myocardial or skeletal muscle ischemia.10 A previous study
from this group found increased plasma LDH in a cohort of
patients with AAS, and expert opinion has indicated LDH assay
as a potential biomarker applicable in the workup of AAS.11–13
Furthermore, increased plasma LDH has been associated with
worse outcome and mortality in other conditions such as
pneumonia, pancreatitis, hemolysis, thrombosis, and bowel
ischemia.14–19 However, evidence supporting the use of plasma
LDH in the diagnosis of AAS, or to predict outcome in patients
with documented AAS, is currently lacking. In the present
study, we sought to evaluate the diagnostic accuracy of plasma
LDH for the diagnosis of AAS and the association of plasma
LDH with in-hospital outcome. The working hypothesis was
that increased plasma LDH at presentation may identify patients
at higher risk of in-hospital death.
METHODS
Study Design, Setting, and Enrolment Criteria
This was a bi-centric prospective diagnostic accuracy and
a cohort outcome study performed on patients from 2 clinical
centers: Molinette Hospital (Torino, Italy) and Careggi Hos-
pital (Firenze, Italy). Both centers are regional hubs for emer-
gency and cardiovascular medicine and surgery. The study
protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki, and was approved by the local Ethics
Committee. The study is compliant with the STARD and
STROBE guidelines.20,21
From January 2008 to June 2014, consecutive outpatients
who presented to the ED were eligible for the study if they had a
clinical suspicion of AAS, defined as an acute onset of chest
pain, back pain, abdominal pain, syncope, or signs/symptoms of
perfusion deficit (including central/peripheral nervous system,
mesenteric, myocardial, or limb ischemia), without another
known etiology. The suspicion of AAS needed to be high
enough for the attending physician to order an urgent aortic
imaging examination, as in previous studies.22–24 Trauma
patients were excluded. Plasma LDH was assayed in a conven-
ience sample of patients meeting inclusion criteria. Informed
consent was obtained from each patient or next of kin.
LDH Assay
A plasma LDH assay was performed on blood collected in
the ED during medical evaluation. Attending physicians caring
for the patients were not blinded to the results of plasma LDH
assay. Patients underwent venipuncture in the ED as part of the
initial diagnostic workup, and venous blood samples were
immediately sent to the local laboratory for plasma LDH assay.
Plasma LDH levels were measured with a Roche/Hitachi Cobas
automated platform, using a colorimetric pyruvate-lactate enzy-
matic assay technique (Cobas LDHL, Roche Diagnostics, Basel,
Switzerland), where LDH catalyzes the following reaction:
pyruvateþNADHþHþ ! L-lactateþNADþ. The initial oxi-
dation velocity of NADH is directly proportional to the catalytic
activity of LDH, which is measured by recording absorbance
reduction at 340 nm. This assay is optimized by the manufacturer
according to theDeutscheGesellschaft fu¨rKlinischeChemie, and
is calibrated on the reference lactate-pyruvate assay standardized
by the International FederationofClinicalChemistry andLabora-
tory Medicine (IFCC).25,26 Intra- and inter-assay coefficient of
Morello et alvariations were <2.3%. The reference values of plasma LDH
levels with this assay are 250 to 450U/L, and are calibrated on the
normal range obtained with the IFCC method.27
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Enrolled patients underwent an urgent aortic imaging
examination for final AAS diagnosis or rule-out in the ED.
The examination used to confirm or to exclude the diagnosis of
AAS was chest and abdomen computed tomography angiogra-
phy (CTA) or transesophageal echocardiography (TEE). CTA
was performed with Lightspeed VCT 64 (GE, Piscataway, NJ)
or with Somatom Definition As4 and AS128 (Siemens, Erlan-
gen, Germany) and interpreted by specialized radiologists not
involved in the present study. TEE was performed with MyLab
30 (Esaote, Genova, Italy) and HD7 (Philips, Amsterdam,
Holland) and interpreted by specialized cardiologists not
involved in the present study.
The results of aortic imaging were used to categorize
patients as affected by AAS or by an alternative diagnosis
(AltD). Two senior emergency physicians established the
AAS subtype or a specific AltD in each study patient after
review of all ED and hospital records, including medical,
radiological, and surgical data. The following diagnoses
were considered in the definition of AAS, according to
guidelines: Stanford type A and type B ‘‘classic’’ AD,
IMH, and PAU.1
Data Collection
Relevant clinical data including presenting signs and
symptoms, medical history, vital signs, and presence/absence
of risk factors for AAS as defined in guidelines were collected
and annotated during patient evaluation in the ED. A team of 4
emergency physicians blinded to LDH levels reviewed ED and
hospital charts and records to obtain data on in-hospital treat-
ment (medical, surgical, and endovascular) and outcome (sur-
vival, death, and date of death). Patients with missing data on in-
hospital treatment or outcome were annotated.
Statistical Analysis
Dichotomous data were expressed as proportions and
compared with Fisher exact test. Continuous data were
expressed as mean and standard deviation for normal variables,
or as median and interquartile range (IQR) for non-normal
variables (including plasma LDH). For normal data, group
comparison was performed with unpaired Student t test. For
non-normal data, group comparison was performed with
Mann–Whitney U test. The diagnostic performance of plasma
LDH was assessed by receiver operated characteristic (ROC)
analysis, estimating the area under the curve (AUC). Sensitivity,
specificity, negative/positive predictive values (NPV, PPV), and
negative/positive likelihood ratios (LR, LRþ) were computed
with their 95% confidence interval (95% CI).
The following variables were evaluated in univariate
analysis for association with mortality: female gender, age 
70 years, female gender, hypertension, diabetes, smoke, chest
pain, back pain, abdominal pain, syncope, Marfan syndrome,
family history of AAS, aortic valve disease, recent aortic manip-
ulation, known thoracic aortic aneurysm, severe pain, abrupt pain,
tearing pain, pulse deficit, neurologic deficit, new diastolic
murmur, hypotension, surgical intervention, endovascular inter-
vention, and LDH  450U/L. The association of categorical
variables with in-hospital mortality was compared using the
Pearson x2 test. We selected for stepwise multivariable logistic
regression the variables showing in univariate analysis at least a
Medicine  Volume 95, Number 6, February 2016trend in association with mortality (P< 0.20 by Pearson x2 test).
The calibration of the multivariable model was evaluated by the
Hosmer–Lemeshow goodness-of-fit test.28 In-hospital mortality
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
count, troponin T, creatinine, and D-dimer, and lower levels of
hemoglobin and fibrinogen, compared to patients with AltD
(Supplementary Table 1, http://links.lww.com/MD/A701).
FIGURE 1. Flow diagram of the study. AAS ¼ acute aortic syn-
TABLE 1. Final Diagnosis in Study Patients
Final Diagnosis n %
Acute aortic syndrome 201 20.1
Stanford type A aortic dissection 115 11.5
Stanford type B aortic dissection 51 5.1
Intramural aortic hematoma 30 3.0
Penetrating aortic ulcer 5 0.5
Alternative diagnosis 798 79.9
Musculoskeletal chest pain 388 38.8
Acute coronary syndrome

90 9.0
Gastrointestinal disease 88 8.9
Syncope

60 6.0
Pericarditis 30 3.0
Pneumonia/pleuritis 14 1.4
Ischemic stroke

22 2.2
Limb ischemia

15 1.5
Pulmonary embolism 13 1.3
Other diagnoses 78 7.8

TABLE 2. Demographic and Clinical Characteristics of Study
Patients Classified by Final Diagnosis
AAS
(n¼ 201)
AltD
(n¼ 798)
P
Value
Demographics
Female gender 72 (35.8) 275 (34.5) 0.13
Age, y 69 12 67 15 0.05
Medical history
Hypertension 130 (64.7) 522 (65.4) 0.85
Smoke 62 (30.8) 185 (23.2) 0.024
Diabetes 17 (8.5) 93 (11.7) 0.20
Clinical presentation
Chest pain 118 (58.7) 491 (61.5) 0.46
Back pain 80 (39.8) 241 (30.2) 0.009
Abdominal pain 50 (24.9) 167 (20.9) 0.23
Syncope 30 (14.9) 109 (13.7) 0.64
Perfusion deficit 54 (26.9) 58 (7.3) <0.001
Systolic blood pressure,
mm Hg
131 37 143 29 <0.001
Diastolic blood pressure,
mm Hg
76 20 82 14 <0.001
Heart rate, bpm 78 20 79 17 0.33
Values are reported as mean standard deviation for continuous
variables, or as absolute number and percent value (in brackets) for
Medicine  Volume 95, Number 6, February 2016 Plasma Lactate Dehydrogenase in Acute Aortic Syndromesin different patient groups was evaluated and compared by
standard Kaplan–Meier plots and log-rank test. P values were
2-sided, and a P value< 0.05 was considered as statistically
significant. Analysis was performed with the SPSS statistical
package 17.0 (SPSS Inc., Chicago, IL) and Prism 5.0 (GraphPad
Software, San Diego, CA).
RESULTS
Study Population
In the study period, 1578 consecutive patients satisfied
inclusion criteria defining clinical suspicion of AAS. Plasma
LDH was assayed in a convenience sample of 999 patients
(Figure 1). The final diagnosis was AAS in 201 (20.1%) patients,
while an AltD was made in 798 (79.9%) patients. Table 1 reports
the prevalence ofAAS subtypes andAltD in the study population.
Patients with AAS and patients with AltD were similar in their
demographic characteristics, except from a higher prevalence of
smokers in patients with AAS (Table 2). Back pain and signs/
symptoms of possible perfusion deficit were more prevalent in
patients with AAS than in patients with AltD, while blood
pressure was significantly lower in patients with AAS.
LDH Levels
Median time from symptom onset to sampling time was 4 h
(IQR 2–12) in patients with AAS and 6 h (IQR 2–24) in patients
with AltD (P¼ 0.043). Median plasma LDH at presentation was
424 U/L (IQR 367–557) in patients with AAS and 383 U/L
(IQR 331–460) in patients with AltD (P< 0.001, Figure 2A).
Among patients with AAS, median LDH level was 443 U/L
(IQR 380–559) in patients with Stanford type A AD, 408 (IQR
drome, AltD ¼ alternative diagnosis, CTA ¼ computed tomogra-
phy angiography.336–500) in patients with Stanford type B AD, 424 U/L (IQR
342–561) in patients with IMH, and 341 U/L (IQR 321–375) in
patients with PAU (P< 0.001, Figure 2B). In patients without
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.AAS, no significant differences were found in LDH levels
among different alternative diagnoses (data not shown). Patients
with AAS also presented increased levels of white blood cell
Not related to acute aortic syndrome.dichotomic variables.
AAS ¼ acute aortic syndrome, AltD ¼ alternative diagnosis, bpm ¼
beats per minute.
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FIGURE 2. Plasma LDH distribution and diagnostic performance
in study patients. (A) Box-whisker graph of LDH in patients with
final diagnosis of acute aortic syndrome (AAS) or alternative
diagnosis (AltD). (B) Box-whisker graph of LDH in patients with
final diagnosis of Stanford type A aortic dissection (Stanf. A) or
other forms of AAS (Stanford type B aortic dissection, intramural
hematoma, and penetrating aortic ulcer). For A and B, central lines
represent median value, boxes represent interquartile range, and
whiskers the 10th to 90th percentile range. Group comparison
was performed with Mann–Whitney nonparametric U test. Data
are presented in a log2 scale. (C) Receiver operated characteristic
curve of LDH for the diagnosis of AAS. (D) Plots of sensitivity
(continuous line) and specificity (dashed line) of LDH for
TABLE 3. Characteristics of Patients With Acute Aortic Syn-
drome Classified According to Plasma LDH Levels (Cutoff
450U/L)
Variables
LDH< 450
U/L (n¼ 112)
LDH  450
U/L (n¼ 89)
P
Value
Demographics and medical history
Female gender 30 (27) 42 (47) 0.001
Age, y 69 12 70 13 0.76
Hypertension 76 (68) 54 (61) 0.29
Diabetes 11 (10) 6 (7) 0.44
Smoke habit 40 (36) 22 (25) 0.09
Clinical presentation
Chest pain 72 (64) 46 (52) 0.07
Back pain 53 (47) 27 (30) 0.015
Abdominal pain 25 (22) 25 (28) 0.35
Syncope 14 (13) 16 (18) 0.28
Perfusion deficit 48 (43) 46 (52) 0.21
Systolic blood
pressure, mm Hg
136 38 125 35 0.038
Diastolic blood
pressure, mm Hg
79 19 73 22 0.043
Heart rate, bpm 77 19 79 20 0.45
Values are reported as mean standard deviation for continuous
variables, or as absolute number and percent value (in brackets) for
dichotomic variables. For continuous variables,P value was obtained by
Student t test. For dichotomic variable, P value was obtained by Fisher
exact test. Perfusion deficit was defined as presence of 1 of the
following findings: pulse deficit, systolic blood pressure differential
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ROC analysis was used to evaluate the diagnostic per-
formance of plasma LDH for AAS (Figure 2C). The AUC of
LDH was 0.61 (95% CI 0.57–0.66, P< 0.001). Diagnostic
sensitivity and specificity values associated with different
plasma LDH cutoffs are presented in Figure 2D. Using the
higher normality cutoff of 450U/L (Figure 1), the sensitivity of
LDH for the diagnosis of AAS was 44% (95% CI 37–51), the
specificity was 73% (95% CI 69–76), the PPV was 29% (95%
CI 24–34), the NPV was 84% (95% CI 81–86), the LRþ was
1.61 (95%CI 1.33–1.95), and the LRwas 0.77 (95%CI 0.67–
0.87). For the diagnosis of Stanford type A AD, the sensitivity
of LDH (cutoff of 450U/L) was 50% (95% CI 40–59), the
specificity was 72% (95% CI 69–75), the PPV was 19%
(95% CI 14–23), the NPV was 92% (95% CI 89–94), the
LRþ was 1.75 (95% CI 1.42–2.17), and the LR was 0.70
(95% CI 0.58–0.85).
We next evaluated the demographic and clinical profile of
AAS patients presenting with increased plasma LDH to the ED
(Table 3). Female gender was more prevalent in AAS patients
with LDH  450U/L. AAS patients with LDH 450U/L were
less likely to present with back pain and more likely to present
with perfusion deficit. Systolic and diastolic blood pressures
were significantly lower in patients with LDH  450U/L.
Furthermore, AAS patients with LDH  450U/L showed
the diagnosis of AAS using different cutoffs. LDH ¼ lactate
dehydrogenase.significantly higher levels of white blood cell count, liver
enzymes, creatine kinase, troponin T, international normalized
ratio, and D-dimer levels than AAS patients with LDH<450U/L
4 | www.md-journal.com(Supplementary Table 2, http://links.lww.com/MD/A701).
Stanford type A AD was diagnosed in 33 of 51 (64.7%) patients
with LDH  450U/L and in 82 of 150 (54.7%) in patients with
LDH< 450U/L (P¼ 0.25).
Association of LDH Levels With In-Hospital
Mortality
Follow-up regarding in-hospital outcome was complete for
193 of 201 (96%) patients with AAS (Figure 1). Median follow-
up was 11 days (IQR 7–17). Aortic surgery was performed on
113 patients (89 with Stanford type A AD and 24 with other
types of AAS) and endovascular intervention was performed on
18 patients (3 with Stanford type A AD and 15 with other types
of AAS). Overall in-hospital mortality for AAS was 23.8%;
mortality was 29.1% (32 out of 110) in patients with Stanford
type A AD and 16.9% (14 out of 83) in patients with other types
of AAS (P¼ 0.06). Furthermore, mortality was 24.8% (28 out
of 113) in surgically treated patients and 22.5% (18 out of 80) in
nonsurgically treated patients (P¼ 0.74).
We next evaluated the association of LDH levels at pres-
entation with in-hospital mortality of AAS. When AAS patients
were stratified according to the higher normality cutoff of LDH
(450U/L), in-hospital mortality was 32.6% in patients with LDH
 450U/L and 16.8% in patients with LDH< 450U/L
(Figure 3A; log-rank 7.6, P¼ 0.006). Furthermore, when AAS
patients were stratified according to LDH quartiles, in-hospital
(>20 mm Hg), neurological deficit, hypotension, or shock state.
LDH ¼ lactate dehydrogenase.mortality was 12% in the first quartile, 18.4% in the second
quartile, 23.5% in the third quartile, and38% in the fourth quartile
(Figure 3B; log-rank 11.4, P¼ 0.010).
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 3. In-hospital mortality of study patients (n¼193) with
acute aortic syndrome stratified according to plasma LDH at
presentation to the Emergency Department. (A) Kaplan–Meier
survivalcurvesofpatientsstratifiedaccordingtothehighernormality
cutoffof LDH(450U/L). (B)Kaplan–Meier survival curvesofpatients
stratified according to quartiles of LDH: Q1 (LDH<367U/L), Q2
Medicine  Volume 95, Number 6, February 2016In univariate analysis, LDH  450U/L was significantly
associated with in-hospital death in AAS. Clinical character-
(LDH 367–424U/L), Q3 (LDH 425–557U/L), Q4 (LDH>557U/L).
LDH ¼ lactate dehydrogenase.istics that also found a significant association with in-hospital
death were female gender, age  70 years, back pain, and
hypotension (Table 4). Variables showing a trend in association
TABLE 4. Univariate and Stepwise Logistic Regression Analysis of
Univariate
Variable OR 95% CI
Female gender 2.01 1.02–3.96
Age  70 y 3.85 1.78–8.34
Smoke 0.56 0.25–1.21
Chest pain 0.63 0.33–1.23
Back pain 0.37 0.17–0.77
Syncope 2.12 0.92–4.86
Severe pain 0.63 0.32–1.24
Hypotension 2.62 1.28–5.37
Endovascular intervention 0.37 0.08–1.68
LDH  450 U/L 2.39 1.21–4.70
The following variables were evaluated for association with in-hospital mo
smoke, chest pain, back pain, abdominal pain, syncope, Marfan syndrome, fa
manipulation, known thoracic aortic aneurysm, severe pain, abrupt pain,
hypotension, surgical intervention, endovascular intervention, and LDH 4
hospital death are shown herein (see the ‘‘Methods’’ section).
95% CI ¼ 95% confidence interval of OR, LDH ¼ lactate dehydrogena
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.with in-hospital death (P< 0.20) were further analyzed in
stepwise logistic regression analysis. Only LDH  450U/L,
age 70 years, and hypotension were identified as independent
predictors of in-hospital mortality in AAS. The Hosmer–Leme-
show statistic was not statistically significant for departure of
observed mortality from predicted mortality (x2¼ 5.78; df ¼ 8;
P¼ 0.45). When data analysis was restricted to 154 of 193
patients with also D-dimer available, also D-dimer> 5.0mg/mL
was found associated with in-hospital death (OR 2.42, 95% CI
1.10–5.38; P¼ 0.03) in univariate analysis. However, D-dimer
was not identified as an independent predictor of in-hospital
mortality in stepwise logistic regression analysis, while LDH
450U/L, age  70 years and hypotension remained significant
also in this subgroup of patients.
The association of LDH levels with in-hospital mortality
was next evaluated in different patient subgroups (Figure 4).
Excess mortality was found in association with LDH 450U/L
in elder patients (n¼ 107, mortality 49.0%with LDH 450U/L
and 20.7% with LDH< 450U/L; OR 3.68, 95% CI 1.58–8.58;
P¼ 0.004), hemodynamically stable patients (n¼ 146, mortality
28.3% with LDH  450U/L and 12.8% with LDH< 450U/L;
OR 2.70, 95% CI 1.16–6.28; P¼ 0.031), and in nonsurgically
treated patients (n¼ 80, mortality 36.4% with LDH  450U/L
and 12.8% with LDH< 450U/L; OR 3.91, 95% CI 1.28–11.88;
P¼ 0.016).
DISCUSSION
This is the first study to specifically evaluate the perform-
ance of plasma LDH for diagnosis and for prognostic stratifica-
tion of AAS. Plasma LDH levels were indeed significantly
elevated in patients with AAS, but the diagnostic sensitivity of
LDH using the standard cutoff of 450U/Lwas negligible (44%).
The specificity was higher (73%), but also appears hardly
suitable for meaningful diagnostic use. A key positive finding
of the present study is that LDH levels were positively associ-
ated with in-hospital mortality in AAS. Regression analysis
Plasma Lactate Dehydrogenase in Acute Aortic Syndromesidentified LDH elevation as an independent predictor of death in
addition to well-established variables such as advanced age and
hypotension.28,29 In univariate analysis, also female gender was
In-Hospital Death in 193 Patients With Acute Aortic Syndrome
Stepwise Logistic Regression
P Value OR 95% CI P Value
0.041
<0.001 4.05 1.82–8.99 0.001
0.136
0.178
0.007
0.073
0.178
0.007 2.52 1.17–5.42 0.018
0.183
0.011 2.28 1.11–4.66 0.025
rtality: female gender, age 70 y, female gender, hypertension, diabetes,
mily history of acute aortic syndrome, aortic valve disease, recent aortic
tearing pain, pulse deficit, neurologic deficit, new diastolic murmur,
50U/L. Only variables showing marginal association (P< 0.20) with in-
se, OR ¼ odds ratio.
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FIGURE 4. Association of plasma LDH levels (cutoff 450U/L) with
in-hospital mortality in patient subgroups. <70y ¼ age<70 y,
70 y ¼ age  70 y, AAS ¼ acute aortic syndrome, LDH ¼ lactate
dehydrogenase, medical ¼ nonsurgical treatment, Other ¼ other
types of AAS (Stanford type B aortic dissection, intramural hema-
toma, and penetrating aortic ulcer), StA ¼ Stanford type A aortic
Morello et alassociatedwithmortality,whichwas also reported previously and
associated with delayed recognition of AD.29,30 Taken together,
our results define LDH as suitable prognostic but not diagnostic
biomarker for AAS.
Our finding that increased LDH is associated with poor
outcome in AAS is novel, while previous studies have
reported an association between LDH and outcome in other
acute conditions such as pneumonia, pancreatitis, hemolysis,
thrombosis, and bowel ischemia.14–19 Of note, subgroup
analysis indicated that high LDH was associated with
increased mortality specifically in patient categories where
risk stratification and therapeutic decisions are more contro-
versial, such as patients with AAS other than Stanford type A
AD, elderly patients and hemodynamically stable patients.
This is relevant, as younger patients with classic type A AD
are noncontroversial candidates for urgent surgery. Therefore,
our results indicate that LDH as an outcome biomarker would
essentially apply to patients without clear-cut surgical indica-
tions such as elderly and comorbid patients, which constitute
increasingly prevalent challenges for clinicians. In hemody-
namically stable and in medically treated patients, for
instance, increased LDH could usefully identify individuals
with subclinical organ damage at increased risk of compli-
cations and death, where advanced treatment options may be
beneficial beyond the tube graft.4
Previous studies have shown that outcomes for acute AD
are highly influenced by presence of organ ischemia and
shock.5,29,31 Other studies have further reported on the cor-
relation between biomarkers and in-hospital mortality in
dissection, stable ¼ hemodynamically stable, surgical ¼ surgical
treatment, unstable ¼ hemodynamically unstable.AAS. In particular, increased mortality has been found in
patients presenting with high levels of D-dimer and C-reac-
tive protein (CRP), and with low levels of platelets.6–9 We
6 | www.md-journal.comalso found increased D-dimer and lower platelet levels in
patients with LDH  450U/L, while CRP was not statisti-
cally different. Although the present study was not powered
to compare the accuracy of different biomarkers for prog-
nostic stratification, in the subgroup of patients with
AAS where both D-dimer and LDH were available, LDH
 450U/L and not D-dimer> 5.0mg/mL was found as an
independent predictor of mortality.
While the present findings identify increased LDH as a
potential biomarker of organ malperfusion-related outcome, the
actual organ/tissue source of LDH in AAS remains uncertain.
The best known tissue sources of LDH aremyocardium, skeletal
muscle, liver, red blood cells, and bowel. Based on routine
biochemical data available only in a minority of study patients,
plasma LDH  450U/L was indeed associated with signifi-
cantly higher levels of troponin T, creatine kinase, and liver
enzymes, while hemoglobin was unchanged. Therefore, myo-
cardial, skeletal muscle, and liver damage/ischemia all appear
as potential sources of plasma LDH rise in AAS, while hemo-
lysis does not appear as quantitatively relevant. Nonetheless,
median levels of troponin T, creatine kinase, and liver enzymes
fell within normal reference limits in AAS patients with LDH
450U/L. The degree of bowel ischemia could not be directly
evaluated in our study due to lack of relevant endpoints.
Limitations
A major limitation of study enrolment criteria is that
patients where AAS was not suspected by treating physicians
were not included, as in previous studies by this and other
groups.22–24 This approach is expected to bias against atypical
and mild presentations, at low pretest probability of AAS, where
nonetheless rule-in and rule-out biomarkers of AAS may be
desirable.1,2 Second, the present study was performed on a
convenience and not on a random sample of 999 patients with
suspected AAS, representing 63% of 1578 clinically eligible
patients, and attending physicians were not blinded to LDH
levels. Although the demographic and clinical characteristics of
study patients are in line with the cohorts of previous studies,
some degree of selection bias in the present cohort cannot be
ruled out.23,24 Third, the absolute LDH levels found in this study
were obtained using a pyruvate-lactate assay, which is different
from, albeit calibrated on, the lactate-pyruvate method recom-
mended by the IFCC. Based on available data, in centers using
an IFCC method for plasma LDH, 220U/L may be considered
as the high-normality cutoff indicating increased mortality risk
in AAS.27 In addition, plasma LDH kinetics may provide more
relevant information rather than a single-point estimate. Indeed,
repeated measures of biomarkers appear desirable particularly
in patients not undergoing urgent intervention, such as in
patients with Stanford type B AD. Finally, as the study was
performed in 2 large hospitals functioning as regional hub
centers, outcome data might not be generalized to different
clinical settings.
CONCLUSIONS
In summary, the results of the present study, performed in a
relatively large patient cohort, question the utility of plasma
LDH as a diagnostic assay in patients with suspected AAS.
Instead, they indicate plasma LDH as a biomarker allowing
improved prognostic stratification of patients with AAS, especi-
Medicine  Volume 95, Number 6, February 2016ally if elderly, hemodynamically stable or not surgically treated.
In clinical practice, results might implicate that special attention
and individualized treatment should be warranted to patients
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
with AAS presenting with elevated LDH, due to their increased
risk of in-hospital death.
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